Thomas N Ferraro
Overview
Explore the profile of Thomas N Ferraro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frost E, Shi S, Byroju V, Rissardo J, Donlon J, Vigilante N, et al.
Brain Sci
. 2025 Jan;
14(12.
PMID: 39766362
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive...
2.
Weller A, Ferraro T, Doyle G, Reiner B, Berrettini W, Crist R
Genes Genomics
. 2024 Jul;
46(9):1071-1084.
PMID: 39083157
Background: Schizophrenia is a mental disorder that causes considerable morbidity, whose risk largely results from genetic factors. Setd1a is a gene implicated in schizophrenia. Objective: To study the gene expression...
3.
McGarry A, Hunter K, Gaughan J, Auinger P, Ferraro T, Pradhan B, et al.
Sci Rep
. 2024 Jan;
14(1):1101.
PMID: 38212353
Huntington's disease (HD) is increasingly recognized for diverse pathology outside of the nervous system. To describe the biology of HD in relation to functional progression, we previously analyzed the plasma...
4.
Kusic D, Heil J, Zajic S, Brangan A, Dairo O, Heil S, et al.
PLoS One
. 2023 Nov;
18(11):e0292674.
PMID: 37910493
The United States continues to be impacted by decades of an opioid misuse epidemic, worsened by the COVID-19 pandemic and by the growing prevalence of highly potent synthetic opioids (HPSO)...
5.
Chen S, Abou-Khalil B, Afawi Z, Ali Q, Amadori E, Anderson A, et al.
medRxiv
. 2023 Mar;
PMID: 36865150
Identifying genetic risk factors for highly heterogeneous disorders like epilepsy remains challenging. Here, we present the largest whole-exome sequencing study of epilepsy to date, with >54,000 human exomes, comprising 20,979...
6.
Weller A, Ferraro T, Doyle G, Reiner B, Crist R, Berrettini W
J Alzheimers Dis
. 2022 Oct;
90(3):1233-1247.
PMID: 36213995
Background: 5XFAD humanized mutant mice and Trem2 knockout (T2KO) mice are two mouse models relevant to the study of Alzheimer's disease (AD)-related pathology. Objective: To determine hippocampal transcriptomic and polyadenylation...
7.
Sardoo A, Zhang S, Ferraro T, Keck T, Chen Y
Brief Bioinform
. 2022 Sep;
23(6).
PMID: 36156112
To understand how distinct memories are formed and stored in the brain is an important and fundamental question in neuroscience and computational biology. A population of neurons, termed engram cells,...
8.
Kusic D, Heil J, Zajic S, Brangan A, Dairo O, Smith G, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145611
Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and...
9.
Reiner B, Zhang Y, Stein L, Davila Perea E, Arauco-Shapiro G, Ben Nathan J, et al.
Transl Psychiatry
. 2022 Sep;
12(1):374.
PMID: 36075888
Opioid exposure is known to cause transcriptomic changes in the nucleus accumbens (NAc). However, no studies to date have investigated cell type-specific transcriptomic changes associated with volitional opioid taking. Here,...
10.
Troiani V, Crist R, Doyle G, Ferraro T, Beiler D, Ranck S, et al.
BMC Med Genomics
. 2021 Oct;
14(1):253.
PMID: 34702274
Background: Prescription opioids (POs) are commonly used to treat moderate to severe chronic pain in the health system setting. Although they improve quality of life for many patients, more work...